Literature DB >> 27995937

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Katherine Fleshner1, Sigrid V Carlsson2,3, Monique J Roobol4.   

Abstract

Guidelines regarding recommendations for PSA screening for early detection of prostate cancer are conflicting. In 2012, the United States Preventive Services Task Force (USPSTF) assigned a grade of D (recommending against screening) for men aged ≥75 years in 2008 and for men of all ages in 2012. Understanding temporal trends in rates of screening before and after the 2012 recommendation in terms of usage patterns in PSA screening, changes in prostate cancer incidence and biopsy patterns, and how the recommendation has influenced physician's and men's attitudes about PSA screening and subsequent ordering of other screening tests is essential within the scope of prostate cancer screening policy. Since the 2012 recommendation, rates of PSA screening decreased by 3-10% in all age groups and across most geographical regions of the USA. Rates of prostate biopsy and prostate cancer incidence have declined in unison, with a shift towards tumours being of higher grade and stage upon detection. Despite the recommendation, some physicians report ongoing willingness to screen appropriately selected men, and many men report intending to continue to ask for the PSA test from their physician. In the coming years, we expect to have an improved understanding of whether these decreased rates of screening will affect prostate cancer metastasis and mortality.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27995937      PMCID: PMC5341610          DOI: 10.1038/nrurol.2016.251

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  76 in total

1.  USPSTF finds little evidence to support advising PSA screening in any man.

Authors:  Anita Slomski
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

3.  Primary care physicians' use of an informed decision-making process for prostate cancer screening.

Authors:  Robert J Volk; Suzanne K Linder; Michael A Kallen; James M Galliher; Mindy S Spano; Patricia Dolan Mullen; Stephen J Spann
Journal:  Ann Fam Med       Date:  2013 Jan-Feb       Impact factor: 5.166

4.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

5.  A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.

Authors:  Simon P Kim; R Jeffrey Karnes; Paul L Nguyen; Jeanette Y Ziegenfuss; R Houston Thompson; Leona C Han; Nilay D Shah; Marc C Smaldone; Cary P Gross; Igor Frank; Christopher J Weight; Timothy J Beebe; Jon C Tilburt
Journal:  BJU Int       Date:  2014-01-17       Impact factor: 5.588

6.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

7.  The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.

Authors:  Homayoun Zargar; Roderick van den Bergh; Daniel Moon; Nathan Lawrentschuk; Anthony Costello; Declan Murphy
Journal:  BJU Int       Date:  2016-08-22       Impact factor: 5.588

8.  Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.

Authors:  Linda B Squiers; Carla M Bann; Suzanne E Dolina; Janice Tzeng; Lauren McCormack; Douglas Kamerow
Journal:  Am J Prev Med       Date:  2013-08       Impact factor: 5.043

9.  The role of increasing detection in the rising incidence of prostate cancer.

Authors:  A L Potosky; B A Miller; P C Albertsen; B S Kramer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

10.  Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision.

Authors:  Kathleen F McGinley; Gregory C McMahon; Gordon A Brown
Journal:  Rev Urol       Date:  2015
View more
  61 in total

1.  Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.

Authors:  Daniel M Frendl; Mara M Epstein; Hassan Fouayzi; Richard Krajenta; Benjamin A Rybicki; Mitchell H Sokoloff
Journal:  Cancer Causes Control       Date:  2020-06-17       Impact factor: 2.506

Review 2.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

3.  Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?

Authors:  Theodorus H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2017-06-13       Impact factor: 14.432

4.  Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.

Authors:  Jarrett A Johnson; Richard P Moser; Gary L Ellison; Damali N Martin
Journal:  J Community Health       Date:  2020-10-16

Review 5.  Cancer Screening and Early Detection in the 21st Century.

Authors:  Jennifer T Loud; Jeanne Murphy
Journal:  Semin Oncol Nurs       Date:  2017-03-23       Impact factor: 2.315

Review 6.  Future Perspectives and Challenges of Prostate MR Imaging.

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Radiol Clin North Am       Date:  2017-12-09       Impact factor: 2.303

7.  Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.

Authors:  Takashi Kobayashi; Kent Kanao; Motoo Araki; Naoki Terada; Yasuyuki Kobayashi; Atsuro Sawada; Takahiro Inoue; Shin Ebara; Toyohiko Watanabe; Tomomi Kamba; Makoto Sumitomo; Yasutomo Nasu; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2017-11-11       Impact factor: 3.402

8.  Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.

Authors:  Scott P Kelly; William F Anderson; Philip S Rosenberg; Michael B Cook
Journal:  Eur Urol Focus       Date:  2017-11-20

9.  Perspective on Prostate Cancer Screening.

Authors:  Sigrid V Carlsson; Hans Lilja
Journal:  Clin Chem       Date:  2018-11-20       Impact factor: 8.327

10.  Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex).

Authors:  Timothy Uzoma Mbaeri; Jideofor Chukwuma Orakwe; Ogochukwu I Ezejiofor
Journal:  Niger J Surg       Date:  2018 Jul-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.